Myriad Genetics, Inc.
NASDAQ: MYGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Samraat S Raha
- Employees
- 2,725
- Headquarters
- Salt Lake City, United States
- IPO year
- 1995
- Market cap
- $493.0M
- Website
- https://www.myriad.com
Loading MYGN…
Loading profile data…Frequently asked questions about MYGN
What does Myriad Genetics, Inc. (MYGN) do?
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic tes...
Where does MYGN trade?
Myriad Genetics, Inc. (MYGN) trades on the NASDAQ.
What sector is MYGN in?
Myriad Genetics, Inc. (MYGN) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Myriad Genetics, Inc.?
Samraat S Raha is the chief executive officer of Myriad Genetics, Inc. (MYGN).
Where is Myriad Genetics, Inc. headquartered?
Myriad Genetics, Inc. is headquartered in United States.
Does MYGN pay a dividend?
Myriad Genetics, Inc. (MYGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MYGN go public?
Myriad Genetics, Inc. (MYGN) completed its initial public offering in 1995.